217 related articles for article (PubMed ID: 37849667)
1. Organotypic Models for Functional Drug Testing of Human Cancers.
Huang YL; Dickerson LK; Kenerson H; Jiang X; Pillarisetty V; Tian Q; Hood L; Gujral TS; Yeung RS
BME Front; 2023; 4():0022. PubMed ID: 37849667
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
[TBL] [Abstract][Full Text] [Related]
3. Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers.
Amirghasemi F; Adjei-Sowah E; Pockaj BA; Nikkhah M
Ann Biomed Eng; 2021 Aug; 49(8):1943-1972. PubMed ID: 33403451
[TBL] [Abstract][Full Text] [Related]
4. Organ-on-Chip platforms to study tumor evolution and chemosensitivity.
Dsouza VL; Kuthethur R; Kabekkodu SP; Chakrabarty S
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188717. PubMed ID: 35304293
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery.
Sivakumar R; Chan M; Shin JS; Nishida-Aoki N; Kenerson HL; Elemento O; Beltran H; Yeung R; Gujral TS
Oncoimmunology; 2019; 8(12):e1670019. PubMed ID: 31741771
[TBL] [Abstract][Full Text] [Related]
7. Multiplexed drug testing of tumor slices using a microfluidic platform.
Horowitz LF; Rodriguez AD; Dereli-Korkut Z; Lin R; Castro K; Mikheev AM; Monnat RJ; Folch A; Rostomily RC
NPJ Precis Oncol; 2020; 4():12. PubMed ID: 32435696
[TBL] [Abstract][Full Text] [Related]
8. Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications.
Chowdury MA; Heileman KL; Moore TA; Young EWK
SLAS Technol; 2019 Oct; 24(5):457-476. PubMed ID: 31173533
[TBL] [Abstract][Full Text] [Related]
9. Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives.
Youhanna S; Kemas AM; Preiss L; Zhou Y; Shen JX; Cakal SD; Paqualini FS; Goparaju SK; Shafagh RZ; Lind JU; Sellgren CM; Lauschke VM
Pharmacol Rev; 2022 Jan; 74(1):141-206. PubMed ID: 35017176
[TBL] [Abstract][Full Text] [Related]
10. Organotypic Models of Lung Cancer.
Pomerenke A
Curr Top Microbiol Immunol; 2021; 430():161-181. PubMed ID: 29423618
[TBL] [Abstract][Full Text] [Related]
11. Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy.
Nicolaides NC; O'Shannessy DJ; Albone E; Grasso L
Front Oncol; 2014; 4():141. PubMed ID: 24982846
[TBL] [Abstract][Full Text] [Related]
12. A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies.
Chadwick EJ; Yang DP; Filbin MG; Mazzola E; Sun Y; Behar O; Pazyra-Murphy MF; Goumnerova L; Ligon KL; Stiles CD; Segal RA
J Vis Exp; 2015 Nov; (105):e53304. PubMed ID: 26575352
[TBL] [Abstract][Full Text] [Related]
13. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
14.
Meijer TG; Naipal KA; Jager A; van Gent DC
Future Sci OA; 2017 Jun; 3(2):FSO190. PubMed ID: 28670477
[TBL] [Abstract][Full Text] [Related]
15. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
Olsen D; Jørgensen JT
Front Oncol; 2014; 4():105. PubMed ID: 24904822
[TBL] [Abstract][Full Text] [Related]
16. Current Trends in Personalized Medicine and Companion Diagnostics: A Summary From the DIA Meeting on Personalized Medicine and Companion Diagnostics.
Tsourounis M; Stuart J; Pignato W; Toscani M; Barone J
Ther Innov Regul Sci; 2015 Jul; 49(4):530-543. PubMed ID: 30222427
[TBL] [Abstract][Full Text] [Related]
17. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.
Tsai S; McOlash L; Palen K; Johnson B; Duris C; Yang Q; Dwinell MB; Hunt B; Evans DB; Gershan J; James MA
BMC Cancer; 2018 Mar; 18(1):335. PubMed ID: 29587663
[TBL] [Abstract][Full Text] [Related]
18. The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform.
Schachtschneider KM; Schwind RM; Newson J; Kinachtchouk N; Rizko M; Mendoza-Elias N; Grippo P; Principe DR; Park A; Overgaard NH; Jungersen G; Garcia KD; Maker AV; Rund LA; Ozer H; Gaba RC; Schook LB
Front Oncol; 2017; 7():190. PubMed ID: 28879168
[TBL] [Abstract][Full Text] [Related]
19. Emerging Translational Opportunities in Comparative Oncology With Companion Canine Cancers: Radiation Oncology.
Nolan MW; Kent MS; Boss MK
Front Oncol; 2019; 9():1291. PubMed ID: 31824863
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Organotypic Systems to Model Tumor Microenvironment in Human Papillomavirus (HPV)-Related Cancers.
De Gregorio V; Urciuolo F; Netti PA; Imparato G
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32375253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
